Delivery Order SPE2DB22D9239-SPE2DB24FDM11

Award Date 8/28/24
Potential Completion Date 9/19/24
Potential Value $109K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $109,272.60 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of XENPOZYME 20 MG VIALS, a specialized pharmaceutical product, with a period of performance through November 6, 2024. DMS Pharmaceutical Group is a key supplier for the DLA, holding a $499,999,999 Indefinite Delivery Contract to...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $109,272.60 firm fixed-price delivery order is for the supply of Xenpozyme 20 mg vials, a specialized pharmaceutical product, with a period of performance through December 31, 2024. This award is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group...
This is a federal contract award from the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is a delivery order worth $87,418.08 for the supply of 4567903324 - XENPOZYME 20 MG VIALS, a specialized pharmaceutical product. The contract is a firm fixed-price arrangement with an ultimate completion date of April 23, 2025. DMS Pharmaceutical Group holds a significant single-award Indefinite Delivery Contract (IDC)...
This federal contract award, valued at $109,272.60, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a for-profit, woman-owned small business based in Park Ridge, Illinois. The delivery order contract is for the supply of XENPOZYME 20 MG VIALS, with a performance period through May 2, 2024. DMS Pharmaceutical Group Inc. holds a larger indefinite delivery contract, contract 4600082013 under the DLA's SPE2DB program, valued at up to $4,999,999 through the end of...
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract valued at $109,272.60 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of XENPOZYME 20 MG VIALS and has an ultimate completion date of April 15, 2024. This delivery order is placed under DMS Pharmaceutical Group's existing indefinite delivery contract with DLA, contract 4600082013 under the SPE2DB program, which is valued at up...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $87,418.08, is a firm fixed-price delivery order for the supply of 4,568,072,383 units of the pharmaceutical product XENPOZYME 20 MG VIALS. The contract has an ultimate completion date of May 7, 2025 and was awarded on April 16, 2025. This delivery order is part of a larger...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $109,272.60 firm fixed-price contract is for the supply of XENPOZYME 20 MG VIALS, a pharmaceutical product. The award falls under a larger indefinite delivery contract (IDC) that DMS Pharmaceutical Group holds with the DLA, valued at up to $499,999,999, to provide a comprehensive range of...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $87,418.08 firm fixed-price contract is for the delivery of XENPOZYME 20 MG VIALS, with a completion date of June 11, 2025. The contract is not set aside for any specific business category. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under...
This is a federal contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $109,272.60, is for the delivery of XENPOZYME 20 MG VIALS, identified by the product code 4564530130. The contract has a firm fixed-price delivery order type and an ultimate completion date of May 16, 2024. This award is associated with a larger indefinite delivery contract (IDC)...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of XENPOZYME 20 MG VIALS, a medical product, with a ceiling value of $87,418.08 and a period of performance through July 25, 2025. DMS Pharmaceutical Group has a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the...
  • SPE2DB22D9239
    Indefinite Delivery Contract
  • SPE2DB22D9239-SPE2DB24FDM11
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $109,272.60 firm fixed-price delivery order contract is for the supply of XENPOZYME 20 MG VIALS, which are likely a specialized pharmaceutical product.

The contract is part of a larger $499,999,999 indefinite delivery contract (IDC) that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program. This single-award IDC allows the DLA to issue delivery orders for a comprehensive range of pharmaceutical items to support the recurring medical supply needs of military health facilities worldwide. DMS Pharmaceutical Group has established itself as a crucial supplier in the federal pharmaceutical supply chain, providing both routine and critical medications to the Department of Defense.

This contract award does not have a set-aside designation, as DMS Pharmaceutical Group's status as a woman-owned small business allows them to secure direct awards for the DLA's pharmaceutical Prime Vendor programs.

Generated 11/27/24, 9:17 AM